# Aldeyra Therapeutics Aldeyra Therapeutics is an Asset Manager based in Lexington, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Lexington, United States - **Region:** North America - **Address:** Lexington, MA, United States - **Founded:** 2004 - **Assets under management:** Undisclosed - **Website:** aldeyra.com ## Regulatory record - **Reports private funds:** No ## About Aldeyra Therapeutics started in 2004, founded by Todd C. Brady to address elevated reactive aldehyde species (RASP) as drivers of inflammatory pathology. Based in Lexington, Massachusetts, the company has focused its entire operational history on discovering and developing novel small-molecule therapeutics that trap these toxic aldehydes, a mechanism distinct from standard anti-inflammatory or immunosuppressive approaches. Its asset base is a concentrated pipeline of wholly owned candidates built around the RASP platform. The lead program, reproxalap, targets dry eye disease and allergic conjunctivitis. In pivotal trials, reproxalap met its primary endpoints in allergic conjunctivitis, but the FDA issued a Complete Response Letter in November 2023 for the dry eye disease indication, citing insufficient data to support efficacy. A second candidate, ADX-2191, designed for vitreoretinal lymphoma and retinitis pigmentosa, received FDA Orphan Drug designation but faced its own regulatory reset when Aldeyra paused development after a Phase 2 analysis. The firm's geographic footprint is US-centric, though its clinical sites span global ophthalmology centers in North America and Europe. Aldeyra has funded its development through equity offerings and at-the-market programs rather than conventional venture fund structures, with no disclosed co-investment vehicles or philanthropic arms. Total deployment to date is not reported as AUM but as cumulative R&D spend; the firm does not manage external capital. In 2024, Aldeyra regrouped around its pipeline and began preparing a resubmission path for reproxalap, citing additional analyses from its trials and ongoing discussions with the FDA. Structurally, Aldeyra's differentiator is its singular focus on the aldehyde-trapping mechanism — a biochemical niche few other public biotechs occupy — combined with a CEO-founder who has maintained the same scientific thesis for two decades. That longevity of scientific commitment, paired with no external capital management mandate, makes the firm's strategic decisions purely pipeline-driven. ## Sectors - Healthcare Services ## People - Todd C. Brady — President, Chief Executive Officer and Director - Bruce Greenberg — Chief Financial Officer - Jim McArthur — Chief Development Officer ## Questions ### What is Aldeyra's core therapeutic mechanism? Aldeyra targets reactive aldehyde species (RASP), which are pro-inflammatory mediators elevated in ocular and systemic inflammatory diseases. The firm's small-molecule candidates act as aldehyde traps, sequestering RASP to reduce inflammation without broadly suppressing the immune system. This mechanism was discovered and has been the sole focus of the company since its 2004 founding by Todd Brady. ### What is the current regulatory status of reproxalap? Reproxalap received a Complete Response Letter from the FDA in November 2023 for its dry eye disease indication. The FDA requested additional efficacy data. Aldeyra subsequently announced plans to resubmit the New Drug Application following further analyses. The candidate had previously met its primary endpoints in two Phase 3 allergic conjunctivitis trials. ### Which indications has Aldeyra pursued beyond dry eye disease? Beyond reproxalap for dry eye disease and allergic conjunctivitis, Aldeyra advanced ADX-2191 for vitreoretinal lymphoma and retinitis pigmentosa, receiving FDA Orphan Drug designation for both. It also investigated reproxalap in a Phase 2 trial for non-infectious anterior uveitis. Development of ADX-2191 was paused after a 2022 analysis. ### Who controls strategic decision-making at Aldeyra? Todd C. Brady, M.D., Ph.D., is the founder, President, and CEO and has led the firm since its inception in 2004. He directs strategic, scientific, and capital allocation decisions. The executive team includes CFO Bruce Greenberg and CDO Jim McArthur, with no disclosed independent investment committee or external advisory board that overrides management. ## Related profiles - [Micropolis AI Robotics](https://altss.com/profile/micropolis-ai-robotics) - [Gold Strike Resources Corp.](https://altss.com/profile/gold-strike-resources-corp) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/aldeyra-therapeutics-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology